Cancer is an important cause of morbidity and mortality worldwide. Advances in research on the biology of cancer revealed alterations in several key pathways underlying tumorigenesis and provided molecular targets for developing new and improved existing therapies. Syndecan-4, a transmembrane heparan sulfate proteoglycan, is a central mediator of cell adhesion, migration and proliferation. Although several studies have demonstrated important roles of syndecan-4 in cell behavior and its interactions with growth factors, extracellular matrix (ECM) molecules and cytoskeletal signaling proteins, less is known about its role and expression in multiple cancer. The data summarized in this review demonstrate that high expression of syndecan-4 is an unfavorable biomarker for estrogen receptor-negative breast cancer, glioma, liver cancer, melanoma, osteosarcoma, papillary thyroid carcinoma and testicular, kidney and bladder cancer. In contrast, in neuroblastoma and colorectal cancer, syndecan-4 is downregulated. Interestingly, syndecan-4 expression is modulated by anticancer drugs. It is upregulated upon treatment with zoledronate and this effect reduces invasion of breast cancer cells. In our recent work, we demonstrated that the syndecan-4 level was reduced after trastuzumab treatment. Similarly, syndecan-4 levels are also reduced after panitumumab treatment. Together, the data found suggest that syndecan-4 level is crucial for understanding the changes involving in malignant transformation, and also demonstrate that syndecan-4 emerges as an important target for cancer therapy and diagnosis.
Heparan sulfate proteoglycans (HSPGs) play important roles in cancer initiation and progression, by interacting with the signaling pathways that affect proliferation, adhesion, invasion and angiogenesis. These roles suggest the possibility of various strategies of regulation of these molecules. In this review, we demonstrated that the anticancer drugs can regulate the heparan sulfate proteoglycans activity in different ways: some act directly in core protein, and can bind to a specific type of HSPG. Others drugs interact with glycosaminoglycans chains, and others can act directly in enzymes that regulate HSPGs levels. We also demonstrated that the HSPGs drug targets can be divided into four groups: monoclonal antibodies, antitumor antibiotic, natural products, and mimetics peptide. Interestingly, many drugs demonstrated in this review are approved by FDA and is used in cancer therapy (Food and Drug Administration) like trastuzumab, panitumumab, bleomycin and bisphosphonate zoledronic acid (ASCO) or are in clinical trials like codrituzumab and genistein. This review should help researchers to understand the mechanism of action of anticancer drugs existing and also may inspire the discovery of new drugs that regulate the heparan sulfate proteoglycans activity. ABSTRACT
Syndecan‐4, a predicted target of the microRNA miR‐140‐3p, plays an important role in multiple steps of tumor progression and is the second most abundant heparan sulfate proteoglycan produced by breast carcinoma cell lines. To investigate the potential functional relationship of miR‐140‐3p and syndecan‐4, MDA‐MB‐231, SKBR3, and MCF‐7 breast cancer (BC) cells were transiently transfected with pre‐miR‐140‐3p, syndecan‐4 small interfering RNAJ, or control reagents, respectively. Altered cell behavior was monitored by adhesion, migration, and invasion chamber assays. Moreover, the prognostic value of syndecan‐4 was assessed by Kaplan–Maier Plotter analysis of gene expression data from tumor samples of 4929 patients. High expression of syndecan‐4 was associated with better relapse‐free survival in the whole collective of BC patients, but correlated with a worse survival in the subgroup of estrogen receptor negative and estrogen/progesterone‐receptor negative patients. miR‐140‐3p expression was associated with improved survival irrespective of hormone receptor status. miR‐140‐3p overexpression induced posttranscriptional downregulation of syndecan‐4, as demonstrated by quantitative real‐time PCR (qPCR), flow cytometry, and luciferase assays, resulting in decreased BC cell migration and matrigel invasiveness. Furthermore, miR‐140‐3p overexpression and syndecan‐4 silencing increased the adhesion of BC to fibronectin and laminin. qPCR analysis demonstrated that syndecan‐4 silencing leads to altered gene expression of adhesion‐related molecules, such as fibronectin and focal adhesion kinase, as well as in the gene expression of the proinvasive factors matrix metalloproteinase 2 and heparanase (also known as HPSE). We conclude that syndecan‐4 is a novel target of miR‐140‐3p that regulates BC cell invasiveness and cell‐matrix interactions in the tumor microenvironment.
Syndecan-4 (SDC4), a heparan sulfate proteoglycan, is aberrantly expressed in breast cancer and plays a significant role in tumor progression by influencing cell proliferation and promoting invasive growth. This study aimed to characterize its role in the tumor microenvironment by analyzing the contribution of SDC4 to vasculogenic mimicry (VM) and angiogenesis in human breast cancer cells. We silenced SDC4 in the triple-negative breast cancer (TNBC) cell lines MDA-MB-231, MDA-MB-468, and SUM-149 and analyzed its functions in vitro. SDC4 knockdown inhibited the VM of MDA-MB-231 cells as analyzed by fluorescence microscopy. Moreover, RT-qPCR revealed decreased expression of KLF4, EGR1, and HPSE, factors involved in VM, proangiogenic and pro-invasive processes in all TNBC cell lines. Western blotting revealed a partially cell-line-dependent regulation of these proteins by SDC4. At the functional level, SDC4 knockdown also impaired angiogenesis, decreasing the number of nodes and meshes in a 3D co-culture model comprising endothelial cells and TNBC cells. Using a Proteome Profile Human Angiogenesis Array, we observed that SDC4 knockdown decreased the secretion of VEGF and IGFBP-1, while it increased the secretion of IL-8, uPA, and amphiregulin in the conditioned media of the MDA-MB-231 and MDA-MB-468 co-cultures. Independent RT-qPCR analyses of gene expression were consistent with those of the angiogenesis array. Overall, these findings highlighted the crucial role of SDC4 in regulating both vasculogenic mimicry and angiogenesis in TNBC cells. The data indicate that SDC4 acts as a crucial regulatory molecule and represents a promising target for therapeutic strategies in breast cancer.
A obesidade é uma doença considerada como epidemia global. No Brasil, a obesidade vem aumentando em todas as faixas etárias sem distinção de sexo. Juntamente com a obesidade outra preocupação surge, o uso indiscriminado e abusivo de medicamentos para tratamento dessa patologia. O objetivo do presente artigo foi identificar quais medicamentos para tratamento da obesidade são mais consumidos na cidade de Teresina-PI. Trata-se de um estudo descritivo de caráter quantitativo e qualitativo com delineamento transversal. A pesquisa foi realizada em 5 drogarias, sendo duas na zona leste, uma na sul, uma norte, e outra na região sudeste da cidade de Teresina. Observou-se que o medicamento mais comercializado para o tratamento da obesidade é a Sibutramina, seguida do Orlistate, Fluoxetina, Duloxitina e Topiramato. Lembrando que os três últimos são medicamentos off label (fora da bula) que são comercializados para o tratamento da ansiedade e depressão. 0 maior atendimento foi para usuários do sexo feminino, entre 20 a 29 anos. Observou-se no estudo que parte dos usuários nem sempre fazem o uso correto desses medicamentos. O culto ao corpo, beleza, status social, a ampla disponibilidade desses medicamentos, e, as influências de terceiros fazem parte desses processos seduzidos pela propaganda das indústrias farmacêuticas.